BPI-7711
Phase 2Small molecule
BPI-7711 is one of 25 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.
1
Indications
5
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Lenvima
EisaiPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
BPI-7711
BBeta Pharma Shanghai
Phase 2
REGN2810
RegeneronPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer3 trials
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BPI-7711. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBeta Pharma Shanghai